CPRIT Product Development Research

CPRIT Product Development Research provides non-dilutive grant funding (~$70 million per year) to Texas-based companies developing novel cancer treatments, devices, diagnostics, and enabling technologies. Unlike typical state grants, awards are backed by Texas General Obligation bonds and require revenue-sharing agreements (royalties, equity, or other arrangements) back to the state — a royalty-back instrument that is genuinely non-dilutive but has a downstream obligation. Four distinct RFAs address different company stages and technology types: Texas Therapeutics Company (near IND/IDE or Phase 1 compounds), Texas Device and Diagnostics Company (near IDE/510(k)/PMA), Texas New Technologies Company (bioinformatics, AI, radionuclides, cell-therapy manufacturing), and Texas Seed Company (company formation and early R&D, capped at $3M). All RFAs accept applications on a rolling basis. Companies outside Texas may apply but must commit to relocating. As of May 2026, CPRIT has funded or brought 72 companies to Texas through this program.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.